Chengdu Kanghong Pharmaceutical Co., Ltd. is developing Compaq Xipu Eye Injection (KH902). Kangsaipu eye injection (KH902) can inhibit the growth of pathological neovascularization by blocking the signal transmission mediated by VEGF, thus treating various fundus neovascularization diseases. These include age-related macular deformation (AMD), diabetic macular edema (DME), pathological myopia (PM) and retinal vein occlusion (RVO).
20 13 12-04, official website, China Food and Drug Administration issued an announcement, and China Food and Drug Administration approved Combep eye injection for the treatment of wet age-related macular degeneration. Age-related macular degeneration (AMD), also known as age-related macular degeneration, is an aging change of macular structure, which is mainly caused by retinal pigment epithelial cells and retinal degeneration, leading to irreversible vision loss or loss. Clinically, the disease is divided into dry (atrophic) AMD and wet (exudative) AMD, which mostly occurs over 45 years old, and the incidence increases with age. With the acceleration of the aging process in China, the incidence of blinding eye diseases caused by wet AMD is increasing year by year, which is one of the main eye diseases that reduce vision and cause blindness in the elderly. The main pathological manifestation of wet age-related macular degeneration is choroidal pathological neovascularization. VEGF is considered as a necessary and important inducer in physiological and pathological angiogenesis. If the activity of VEGF can be inhibited, angiogenesis can be effectively controlled. Compaxil eye injection approved by China Food and Drug Administration is a new kind of therapeutic biological products and a fusion protein of VEGF receptor and human immunoglobulin Fc segment gene recombination. By binding vascular endothelial growth factor VEGF, the drug competitively inhibits the binding between VEGF and its receptor and prevents the activation of VEGF family receptors, thus inhibiting the proliferation and angiogenesis of endothelial cells and achieving the purpose of treating wet age-related macular degeneration. Compaxip eye injection is the first drug independently developed in China to treat this disease, which is of positive significance to solve the accessibility of clinical drugs in China. Compaxip ophthalmic injection is administered by intravitreal injection and should be used in qualified hospitals and ophthalmologists.
20 13 12.23, official website, China Food and Drug Administration issued the Announcement of Drug GMP Certification (No.14), and Chengdu Kanghong Biotechnology Co., Ltd. was approved to meet the requirements of good manufacturing practice (revised on 20 10) after on-site inspection and audit. CertificateNo. Enterprise Name and Address Certification Scope The certification date is valid until the issuing authority CN20 130483 Chengdu Kanghong Biotechnology Co., Ltd. Kangbai Xipu Eye Injection Chengdu jinniu district Shu Xi Road1082012.23201812.22 China Food and Drug Administration.